This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare.

Case presentation

We present the first case of low-grade ESOS of the chest wall, which occurred in a
30-year-old man. Because of initial misdiagnosis and patient's refusal of surgery,
the diagnosis was done after a 4-year history of a slowly growing mass in soft tissues,
leading to a huge (30-cm diameter) calcified mass locally extended over the left chest
wall. Final diagnosis was helped by molecular analysis of MDM2 and CDK4 oncogenes. Unfortunately, at this time, no surgical treatment was possible due to
loco-regional extension, and despite chemotherapy, the patient died one year after
diagnosis, five years after the first symptoms.

Conclusion

We describe the clinical, radiological and bio-pathological features of this unique
case, and review the literature concerning low-grade ESOS. Our case highlights the
diagnostic difficulties for such very rare tumours and the interest of molecular analysis
in ambiguous cases.

Background

Osteosarcoma (OS) typically develops in the intramedullary cavity of long bones of
adolescents and young adults and is a high-grade tumour [1,2]. Extraskeletal osteosarcoma (ESOS) is a very rare form of OS (~5%) located in the
soft tissues without connection to the skeleton. Its usual aspect is that of a large
and deep high-grade bone-forming sarcoma, developed in the limbs of patients older
than 40 years [2,3], with a very aggressive behaviour [4].

Low-grade ESOS, whose histology is similar to well-differentiated intraosseous and
parosteal OS, is extremely rare. To date only six cases have been reported in the
literature. Here, we describe a new case of low-grade ESOS, which developed in the
chest wall. Initial diagnosis, based on radiological and histological aspects, was
erroneously myositis ossificans. Correct final diagnosis, suspected by the clinical
evolution, was confirmed by molecular analysis, but was too late, and the patient
died from extensive loco-regional progression. We hope that this case report underlines
the diagnostic difficulties of this tumour, and the interest of molecular analysis
in ambiguous cases.

Case presentation

The patient was a 30-year-old man, Caucasian type, without any specific medical personal
or familial history. He was referred to our institution in November 2006 for diagnosis
and treatment of a huge tumour of the left chest wall, detected for the first time
4 years earlier. Indeed, in May 2002, he presented a 3-cm painless, mobile, intramuscular
mass on the left shoulder near scapula, three months after a benign trauma on this
region. Magnetic resonance imaging (MRI) showed elements in favour of a myositis ossificans
circumscripta. Percutaneous biopsy showed areas of osteogenesis with mature bone trabeculae
in muscle. The intertrabecular space revealed benign-appearing fibroblastic proliferation.
The retained diagnosis was myositis ossificans. The benignity of this disease with
usual spontaneous stabilisation or regression [5], and the lack of functional impact of the lesion led the physicians to decide observation.

However, the patient was lost to follow-up, and the mass continued to grow slowly
during two years. A second percutaneous biopsy was performed in May 2004. Histological
analysis showed an intramuscular tumour made of bland fusiform cells with few mitoses
and mature bone trabeculae (Figure 1). The morphological features were quite similar to that of the first biopsy, but
with some worrisome features such as the absence of classical "zonal phenomenon",
and more florid fusiform proliferation and bone forming. Because of the long clinical
history and the pathological aspect, the diagnoses of "atypical" myositis ossificans
or heterotopic ossification were evoked and a surgical removal was proposed. The patient
refused, and consulted another physician who prescribed diphosphonate treatment during
a few months.

The patient was then lost to follow-up during 17 months until November 2006, when
he was referred to our institution because the mass had kept growing, leading to a
shoulder immobilisation. The ECOG status was 1, and the patient presented a frozen
left shoulder associated with ipsilateral radial and cubital paralysis and cervical
pain. Physical examination found a voluminous, plane, hard and immobile mass extended
from the basicervical region to the scapulo-humeral joint and from the left side of
the chest wall to the axillary region. Biologically, there was not any abnormality
except an elevation of serum alkaline phosphatases. Radiological images were impressive.
CT scan showed a huge calcified heterogeneous mass, with kystic and solid elements
(Figure 2A). The mass had a 25-cm transversal diameter, an 18-cm antero-posterior diameter and
a 30-cm cranio-caudal diameter. It included the left scapula, the periscapular muscles
and the chest wall, with intercostal invasion to the pleura and muscular extension
to the left arm (triceps). Tc99 bone scan showed a large hyperfixation of the whole
left side of the chest (Figure 2B). PET-scan with 18-FDG showed the mass localised in the chest left side, crossing
the median line at the first sternocostal joint. Hyperfixation was heterogeneous and
moderate with a few highly metabolic zones. A subcutaneous lesion was also observed
in the right pectoral muscle (SUV max = 7 g/ml), as well as pleural abnormalities.

Figure 2.Radiological features 4.5 years after the first symptoms. (A) CT scan: thoracic transversal view showing a voluminous heterogeneous highly calcified
mass. It included the whole left chest wall and the left scapula, with intercostal
invasion to the apical pleura (black arrows) and the antero-superior mediastinum (bolt)
with trachea deflection to the right. (B) Bone scan with Technecium 99: see the heterogeneous extended hyperfixation of the
whole left side of the chest. There was a muscular extension to the triceps leading
to a frozen scapulo-humeral joint.

The diagnosis of low-grade ESOS was strongly suspected. For confirmation, the pathological
samples removed in May 2004 were collected for re-examination, and notably for molecular
analysis of MDM2 and CDK4 oncogenes, whose amplification had been reported in low-grade intraosseous and parosteal
osteosarcomas [6-9]. As shown in Figure 3A-B, CDK4 displayed a strong nuclear staining of fusiform cells by immunohistochemistry
(IHC), whereas MDM2 had a more focal positivity. Fluorescence in situ hybridization (FISH) analysis showed high amplification for both MDM2 and CDK4 (Figure 3C), confirming the diagnosis of low-grade ESOS.

Unfortunately at this time, more than 4 years after the first symptoms, curative surgical
resection was not possible because of to the loco-regional extension. We delivered
chemotherapy with an API/AI sequential regimen, which combined adriamycin (A), cisplatinum
(P) and ifosfamide (I). The disease was stable after 2 API/AI cycles. After 4 additional
API cycles, the disease progressed with extension of cutaneous nodules and tumour
mass associated to the apparition of left pleuritis. The ECOG status was 3, and the
patient complained of thoracic pain and dyspnoea. Palliative radiation therapy was
not possible technically due to the tumour volume. A thoracoscopic talcage was done,
followed by trabectedin-based chemotherapy. Three weeks after the first cycle, the
patient deteriorated rapidly and died of respiratory failure secondary to loco-regional
extension, 5 years after the initial symptoms.

Discussion

Low-grade ESOS are extremely rare with only 6 cases reported to date in the English
literature since 1953 [10-14]. To our knowledge, the present case is the seventh case reported, and the first one
developed in the chest wall.

These cases are summarised in Table 1. The sex ratio is 4 F/3 M, and the median age is 40 years. These tumours likely arise
from the sarcomatous transformation of multipotent mesenchymal cells contained in
soft tissues. Evolution is slow, and the diagnosis is delayed with a median interval
after the discovery of the mass of 4 years (range, 2 to 10 years). This delay explains
the large size of tumours at diagnosis (median 14 cm, ranging from 5 to 30 cm). However,
high-grade histological features (dedifferentiation and high mitotic activity) may
appear after a long period in analogy to what happens in low-grade parosteal OS, thus
leading to accelerated evolution, like in our case with rapid loco-regional extension,
or in two cases with metastatic diffusion [10,14]. Early diagnosis of this tumour is crucial to allow an adequate surgical resection,
which represents the sole curative treatment, as confirmed by the prolonged complete
remissions observed in the 4 out of 5 patients initially treated with complete surgery.

However, differential diagnosis may be problematic at early stages with other ossified
lesions of soft tissues: benign lesions such as myositis ossificans circumscripta
(MOC), ossifying lipoma, soft tissue osteoma or chondroma, and ossifying fibromyxoid
tumour, as well as malignant lesions such as classical high-grade ESOS, parosteal
OS, mesenchymal chondrosarcoma, and synovial sarcoma. MOC is a benign heterotopic
ossification of soft tissues characteristically associated with direct trauma [15]. It is one of the most important differential diagnoses, which was initially evoked
- based on radiological and/or pathological aspects - in at least 3 out of the 7 reported
cases of low-grade ESOS. Furthermore, a number of cases of ESOS presumably arising
from MOC have been reported [16-19]. In MOC, both mature and immature bone is seen, as well as a prominent spindle cell
and chondroid component, with a specific architecture described as the "zonal phenomenon".
This phenomenon refers to the presence of a clearly benign, reactive rim of mature
bone at the periphery, which encompasses a central area of fusiform cells and immature
bone interlaced with osteoid and chondroid. In our patient, several initial aspects
led physicians to erroneously propose this diagnosis: i) the initial traumatism a
few weeks before the discovery of the tumour, ii) the first MRI observation which
showed an extraosseous mass with a mature calcification peripherally predominant,
iii) and the pathological aspects of mature lamellar bone synthesis by non atypical
cells without abnormal mitoses. However, the radiological modifications observed later
with the development of a centrifuge ossification corresponding to microscopic features
to a reverse pattern of ossification ("reverse zonal phenomenon"), and of course,
the progressive tumour growth and extension were that of a malignant tumour. Due to
the initial misdiagnosis followed by the absence of follow-up, and the patient's refusal
of surgery, the correct diagnosis was done too late and evolution was fatal.

Today, molecular analyses may resolve the diagnostic dilemma between low-grade ESOS
and benign lesions. Amplification of genes in the 12q13-15 region, such as SAS, CDK4 and MDM2, is relatively frequent in osteosarcoma, notably in low-grade parosteal OS, making
them suitable as markers for distinguishing them from benign ossifying [6-9]. In our patient, IHC and FISH analyses for MDM2 and CDK4 were done on 2006 from paraffin-embedded tumour samples biopsied on 2004. They showed
the overexpression and amplification of these two oncogenes, thus ruling out the diagnosis
of myositis ossificans and confirming that of sarcoma. To our knowledge, it is the
first case of low-grade ESOS with documented molecular alterations.

Conclusion

Our case is the seventh case of low-grade ESOS reported in literature, and the first
case located in the chest wall. It highlights the importance and difficulty of early
diagnosis of this very rare tumour, which may be confused with numerous benign diseases,
notably myositis ossificans. Misdiagnosis may be fatal, as surgery is the only curative
approach for these patients. In this context, it is worth noting the importance of
molecular analysis (amplification and/or ovexpression of MDM2 and CDK4) to help diagnosis in ambiguous cases.

Consent

Written informed consent was obtained from the patient's relatives for publication
of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RS and FB conceived and designed the study, and wrote the manuscript. FB, PJW, PV,
AS and IBR participated in patient's management. CB, GdP, FP, BC made the pathological
and molecular explorations. All authors read and approved the final manuscript.

Umiker W, Jaffe HL: Ossifying fibrosarcoma (extraskeletal osteogenic sarcoma) of thigh muscle; report
of a case with recurrence and widespread metastases more than four and a half years
after excision.